Spexis AG
PPHOF
Other OTC2.50
USD
- -
- -
Return %
Stock
S&P500
1Y
- -
19.01
3Y
- -
65.48
5Y
- -
72.20
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- IPO Date
- Feb 9, 2021
- Similar Companies
- Business
- Spexis AG (OTC:PPHOF), formerly Polyphor AG, operates as a clinical-stage biopharmaceutical company focused on discovering, developing, in-licensing, and acquiring first-in-class macrocyclic peptide molecules for rare diseases, oncology, and antimicrobial resistance. The company maintains a pipeline that includes ColiFin, an inhaled colistimethate sodium product in phase 3 trials for cystic fibrosis infections; Inhaled Murepavadin, a novel inhaled antibiotic in phase 1 for Pseudomonas aeruginosa infections in cystic fibrosis patients; EBX-002 targeting non-tuberculous mycobacterial lung infections; Balixafortide, a CXCR4 inhibitor for oncology and non-oncology indications; new CXCR4 programs for orphan and hematological malignancies; and outer membrane protein targeting antibiotic BamA and lipopolysaccharide transport protein A programs. Founded in 1996 through its predecessor Polyphor AG and headquartered at Hegenheimermattweg 125 in Allschwil, Switzerland, Spexis conducts operations primarily from Switzerland with historical research ties in Boston, US, targeting patients with high unmet needs in chronic respiratory diseases, rare disorders, and cancer. Recent developments include the termination of its ColiFin license by PARI Pharma GmbH in July 2024; grant of definitive moratorium status until November 25, 2024, with extensions for 2023 financial audits amid delays; trading suspension by SIX Swiss Exchange followed by an imminent delisting announcement in November 2024; and multiple extensions for annual report publication through mid-2024, reflecting ongoing financial and operational restructuring efforts.